
    
      The Primary Objective of this post-market registry is to collect specific health and patient
      characteristics to understand the indication for TA-TAVI and to further evaluate the safety
      and performance of the ACURATE neo ™ Aortic Bioprosthesis and ACURATE neo™ TA Transapical
      Delivery System in a specific TA population, consisting of 200 consented patients.
    
  